JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

20.83 -2.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.07

Максимум

21.59

Ключови измерители
By Trading Economics
Приходи	-7.3M -68M
Продажби	23M 68M
Марж на печалбата	-99.318
Служители	298
EBITDA	42M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+84.95% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	368M 2.1B
Предишно отваряне	23.68
Предишно затваряне	20.83

Настроения в новините

By Acuity

50%

141 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank -2-

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

26.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Dollar's Strength -- Market Talk

26.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

84.95% нагоре

12-месечна прогноза

Среден 39.56 USD 84.95%

Висок 57 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

141 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.